BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 456627)

  • 21. Contraceptive practices of women after abortion in Turkey.
    Karabacak O; Arslan M; Eren LC; Erdem A
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):129-33. PubMed ID: 11763975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.
    Nilsson CG; Allonen H; Diaz J; Luukkainen T
    Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of contraceptives prior to and after conception and exposure to other fetal hazards.
    Shino PH; Harlap S; Ramcharan S; Berendes H; Gupta S; Pellegrin F
    Contraception; 1979 Aug; 20(2):105-20. PubMed ID: 487814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuation and satisfaction of reversible contraception.
    Peipert JF; Zhao Q; Allsworth JE; Petrosky E; Madden T; Eisenberg D; Secura G
    Obstet Gynecol; 2011 May; 117(5):1105-1113. PubMed ID: 21508749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrauterine contraceptive device use and pelvic inflammatory disease.
    Kaufman DW; Shapiro S; Rosenberg L; Monson RR; Miettinen OS; Stolley PD; Slone D
    Am J Obstet Gynecol; 1980 Jan; 136(2):159-62. PubMed ID: 7352496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current assessment of the use of intrauterine devices.
    Westhoff CL
    J Nurse Midwifery; 1996; 41(3):218-23. PubMed ID: 8708805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year follow up of contraceptive use and pregnancy rates after early medical abortion: Secondary outcomes from a randomized controlled trial of immediate post-abortion placement of intrauterine devices.
    Hogmark S; Envall N; Gemzell-Danielsson K; Kopp Kallner H
    Acta Obstet Gynecol Scand; 2023 Dec; 102(12):1694-1702. PubMed ID: 37614066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contraception in Sweden.
    Riphagen FE; von Schoultz B
    Contraception; 1989 Jun; 39(6):633-42. PubMed ID: 2752752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate postplacental insertion of GYNE-T 380 and GYNE-T 380 postpartum intrauterine contraceptive devices: randomized study.
    Tatum HJ; Beltran RS; Ramos R; Van Kets H; Sivin I; Schmidt FH
    Am J Obstet Gynecol; 1996 Nov; 175(5):1231-5. PubMed ID: 8942493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends and determinants of postabortion contraception use in a Canadian retrospective cohort.
    Burk JC; Norman WV
    Contraception; 2019 Aug; 100(2):96-100. PubMed ID: 31100218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible contraception for the woman over 35 years of age.
    Archer DF
    Curr Opin Obstet Gynecol; 1992 Dec; 4(6):891-6. PubMed ID: 1450355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review.
    Usinger KM; Gola SB; Weis M; Smaldone A
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):659-667. PubMed ID: 27386754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective New Zealand study of fertility after removal of copper intrauterine contraceptive devices for conception and because of complications: a four-year study.
    Wilson JC
    Am J Obstet Gynecol; 1989 Feb; 160(2):391-6. PubMed ID: 2916624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical study of the TCu-380 A and the TCu-200 B. IUDs.
    Kandil OF; El-sheikha Z; Hamza A
    Popul Sci; 1991 Jan; 10():35-40. PubMed ID: 12284660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contraception and the etiology of pelvic inflammatory disease: new perspectives.
    Senanayake P; Kramer DG
    Am J Obstet Gynecol; 1980 Dec; 138(7 Pt 2):852-60. PubMed ID: 7008602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time to conception after IUD removal: importance of duration of use, IUD type, pelvic inflammatory disease and age.
    Andolsek L; Teeter RA; Kozuh-Novak M; Wheeler R; Fortney JA; Rosenberg MJ
    Int J Gynaecol Obstet; 1986 Jun; 24(3):217-23. PubMed ID: 2880761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceptability study of the two versus three monthly injectable contraceptives.
    Aly FA; El-genedi MM; Toppozada HK; El-abd M; Loutfi I
    Dirasat Sukkaniyah; 1984; 11(69):27-39. PubMed ID: 12179796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [IUDs and ectopic pregnancy].
    Sivin I
    Contracept Fertil Sex (Paris); 1983 Dec; 11(12):1287-94. PubMed ID: 12312723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The end of IUD marketing in the United States: what does it mean for American women?].
    Forrest JD
    Contracept Fertil Sex (Paris); 1987 Mar; 15(3):291-300. PubMed ID: 12341479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pelvic inflammatory disease among women using copper IUDs, Progestasert, oral contraceptive pills or vaginal contraceptive pills: a 4-year prospective investigation.
    Larsson B; Rodau S; Patek E
    Contracept Deliv Syst; 1981 Jul; 2(3):237-42. PubMed ID: 12278910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.